

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Group Art Unit: 1656  
 )  
 Heid and Livak ) Examiner: Tung, J.  
 )  
 Serial No.: To be assigned )  
 )  
 Filed: March 15, 2002 (herewith) )  
 )  
 For: EXTERNAL CONTROL REAGENTS )  
 FOR NUCLEIC ACID AMPLIFICATION )

## CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service and addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on

EL 897 622435 US

Express Mail Number

MARCH 15, 2002

Date of Deposit

theri Gomez

Name of Depositing Party

Phoi Long

Signature of Depositing Party

11002 U.S. PTO  
 10/099738  
 03/15/02

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
 Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) ☒ [X] accompanies a new patent application submitted herewith.
- (b) ☐ [ ] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) ☐ [ ] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.

- (d) ☐ as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.
- (e) ☐ is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under § 1.113, a notice of allowance under § 1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**
- (f) ☐ is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR § 1.17(i)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR § 1.97(e) may need to be completed.] The undersigned certifies that:

- ☐ Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(e) more than three months prior to the filing of this information disclosure statement.

A copy of the items on PTO-1449 is supplied herewith:

☐ each ☒ none ☐ only those listed below:

Those patent(s) or publication(s) listed in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/645,959, filed August 24, 2000 and relied upon in this application for an earlier filing date under 35 USC §120.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: March 14, 2002



Alex Andrus, Reg. No. 44,509  
Agent for Applicants

**Correspondence Address**  
Customer Number 22896  
Applied Biosystems Division  
PE Corporation (NY)  
850 Lincoln Centre Drive  
Foster City, CA 94404  
(650) 638-5607 (Phone)  
(650) 638-6677 (Fax)

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	To be assigned
<i>(Use as many sheets as necessary)</i>				<b>Filing Date</b>	March 15, 2002
				<b>First Named Inventor</b>	Christian A. Heid
				<b>Group Art Unit</b>	1656
				<b>Examiner Name</b>	Tung, J.
				<b>Attorney Docket No.</b>	4498C1

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

<b>Application Number</b>	To be assigned
<b>Filing Date</b>	March 15, 2002
<b>First Named Inventor</b>	Christian A. Heid
<b>Group Art Unit</b>	1656
<b>Examiner Name</b>	Tung, J.
<b>Attorney Docket No.</b>	4498C1

<b>Filing Date</b>	March 15, 2002
--------------------	----------------

First Named Inventor	Christian A. Heid
----------------------	-------------------

Group Art Unit	1656
----------------	------

Examiner Name	Tung, J.
---------------	----------

Attorney Docket No.	4498C1
---------------------	--------

11002 W. S. PTO

10/099738

03/15/02

## U.S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 30762.1

Please type a plus sign (+) inside this box.

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	To be assigned
		<b>Filing Date</b>	March 15, 2002
		<b>First Named Inventor</b>	Christian A. Heid
		<b>Group Art Unit</b>	1656
		<b>Examiner Name</b>	Tung, J.
		<b>Attorney Docket No.</b>	4498C1
<b>Sheet</b>	2	of	2

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	05	COEN, Donald M., "Quantification of DNAs by the Polymerase Chain Reaction Using an Internal Control, 'The Polymerase Chain Reaction'" pp. 89-96 (1994).	
	06	COREY, E. et al., "Improved Reverse Transcriptase-Polymerase Chain Reaction Protocol with Exogenous Internal Competitive Control for Prostate-Specific Antigen mRNA in Blood and Bone Marrow," <i>Clinical Chemistry</i> , 43:3, pp. 443-452 (1997).	
	07	GIBSON, et al., "A Novel Method for Real Time Quantitative RT-PCR," <i>Genome Research</i> , 6:995-1001 (1996).	
	08	GILLES, et al., "Single Nucleotide Polymorphic Discrimination by an Electronic Dot Blot Assay on Semiconductor Microchips," <i>Nature Biotechnology</i> , Vol. 17, pp. 365-370 (1999).	
	09	HEID, et al., "Real Time Quantitative PCR," <i>Genome Research</i> , 6:986-994 (1996).	
	10	LIVAK, Kenneth J., "Allelic Discrimination Using Fluorogenic Probes and the 5' Nuclease Assay," <i>Genetic Analysis: Biomolecular Engineering</i> , 14:143-149 (1999).	
	11	REISCHL, et al., "Quantitative PCR A Survey of the Present Technology," <i>Molecular Biotechnology</i> , Vol. 3, pp. 55-71 (1995).	
	12	"Primer Express Version 1.5 and TaqMan MGB Probes for Allelic Discrimination," <i>User Bulletin</i> , Applied Biosystems, pp. 1-28, May 26, 2000.	
	13	"TaqMan® Allelic Discrimination Demonstration Kit," <i>Protocol</i> , PE Applied Biosystems, pp. 1-35 (1998).	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

30702\_1